Hercules Capital Inc (HCXY)
Valuation Overview•Is Hercules Capital Inc Overvalued or Undervalued?
Commands a peer premium multiple, but this multiple is justified by a strong intrinsic cash flow value.
Moderate quality score of 58/100, reflecting stable operating margins and manageable leverage.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: Average quality business weighed down by significant solvency concerns.
Wall Street sentiment is generally neutral alongside robust expected earnings growth. This outlook is strongly supported by highly attractive capital returns, anchored by a strong, well-covered dividend yield.
HCXY demonstrates strong business quality with robust profitability and healthy margins. However, the balance sheet carries elevated leverage, requiring careful monitoring of debt servicing capabilities.
The company maintains stable top-line performance paired with highly explosive earnings growth (32.8% EPS 3Y CAGR). This growth is supported by elite operational efficiency, sustaining an impressive 64.9% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $95.9M | +27.0% | — | — | +15.8% | |
| EBITDA | $42.6M | — | +52.9% | — | — | |
| Net Income | $42.5M | +29.2% | +49.3% | — | +23.0% | |
| EPS (Diluted) | $0.23 | +14.9% | +32.8% | -1.6% | +12.1% | |
| Free Cash Flow | -$230.6M | -258.5% | -0.1% | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 85.8% | 85.2% | 83.0% | 81.4% |
| Operating Margin | 64.9% | 65.4% | 59.0% | 55.4% |
| Net Margin | 60.3% | 63.8% | 58.1% | 54.9% |
| FCF Margin | -63.9% | -30.6% | -45.6% | -50.0% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.48 | $0.23 | -52.0% | ||
| Q1'26 | $0.49 | $0.48 | -2.5% | ||
| Q4'25 | $0.48 | $0.61 | +27.3% | ||
| Q3'25 | $0.47 | $0.41 | -12.9% | ||
| Q2'25 | $0.46 | $0.45 | -3.1% | ||
| Q4'23 | — | $0.76 | — | ||
| Q4'22 | — | $773.22 | — | ||
| Q3'22 | — | $386.61 | — |
Total return is +5.4% (1Y), lagging the benchmark by -14.4%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +1.5% | -7.0% | — |
| 1Y | +5.4% | -14.4% | +6.2% |
| 3YCAGR | +6.7% | -12.4% | +19.3% |
| 5YCAGR | +4.0% | -7.5% | +28.8% |
| 10YCAGR | +4.3% | -9.4% | — |
The S&P 500 is at 31.4x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Hercules Capital Inc (HCXY) valuation, health, and returns.
Hercules Capital Inc is estimated to be undervalued under our discounted cash flow framework. relative multiples indicate the stock is Expensive versus peers compared to industry peers. undervalued (implying +51.4% upside to DCF intrinsic value of $37.99)
Hercules Capital Inc has multiple valuation anchors: DCF Intrinsic Value: $37.99 | Peer Relative Fair Value: $15.21. A convergence of these signals offers higher conviction.
Hercules Capital Inc displays fair financial health with a composite quality score of 58/100, supported by a Altman Z-Score of 0.7 (distress zone), Piotroski F-Score of 5/9, Return on Invested Capital (ROIC) of 6.6%.
Hercules Capital Inc pays a 5.6% dividend yield, covered by a 81% payout ratio with 0 years of growth, supplemented by a 0.2% buyback yield.
Hercules Capital Inc's current growth trajectory is Decelerating. The company achieved +27.0% 1Y revenue growth and +14.9% 1Y EPS growth, compared to its 3Y revenue CAGR of N/A.
Wall Street consensus is Hold based on 0 analysts, beating EPS expectations in 20% of recent quarters with a -2-quarter streak. The consensus price target represents a N/A change from current levels.
Investment risks for Hercules Capital Inc include: -76.9% 1-year max drawdown, elevated distress risk. Volatility risk is characterized by a beta of 0.48x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.